Compare Abeona Therapeutics Inc (ABEO) vs Diageo plc (DEO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Diageo plc — how do they compare? Abeona Therapeutics Inc trades at $6.75 (market cap $373.32M), while Diageo plc trades at $81.16 (market cap $45.92B). The key difference: Diageo plc is far larger — about 123× Abeona Therapeutics Inc's market cap, and Diageo plc pays a 4.01% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | DEO | |
|---|---|---|
Market Cap | $373.32M | $45.92B |
Sector | Health | Technology |
52-Week High | $7.23 | $115.33 |
52-Week Low | $4.17 | $72.47 |
Enterprise Value | $228.22M | $66.74B |
Dividend Yield | — | 4.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Diageo (DEO) trades at $81.67, down 0.6% on the day, with a neutral technical signal and mixed earnings history. The stock shows strong profitability with a 12.19% net margin and 22.29% ROE, but faces headwinds in the US spirits market. Recent news highlights CEO Dave Lewis's upcoming strategy update amid concerns over US demand and promotional pressures.
The outlook is cautious with analyst consensus leaning buy (48.65%) but significant hold ratings (43.24%). Key risks include US market weakness and shifting consumer trends, while opportunities lie in premiumization and innovation. The stock's valuation at a P/E of 18.87 appears reasonable if recovery initiatives gain traction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →
